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the literature has not devoted much attention to the last.
Methods: In	our	retrospective	study	involving	25	patients	with	established	GLUT1DS	
diagnosis,	we	describe	the	cognitive	impairment	of	these	patients	in	detail	and	their	
response to the ketogenic diet in terms of cognitive improvement.






p‐value	=	0.015).	We	 found	 a	 significant	 direct	 correlation	between	 cognition	 and	
CSF/blood	 glucose	 ratio	 values:	 the	 higher	 the	 ratio,	 the	 better	 the	 cognitive	 im‐
provement	 in	 response	 to	 diet	 (from	 T0–baseline	 evaluation	 to	 T1	 on	 average	
18	months	after	introduction	of	KD‐:	TIQ	correlation	coefficient	0.592,	p‐value = 0.26; 
VIQ	correlation	coefficient	0.555,	p‐value	=	0.039).	Finally,	we	demonstrated	that	a	
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1  | INTRODUC TION





at	 current	 time	 the	 gold	 standard	 therapy	 for	GLUT1DS	 (Klepper,	
2008).
Since	the	first	description	of	the	disease	by	De	Vivo	et	al.	(1991),	




dyskinesia	 [PKD],	 paroxysmal	 nonkinesigenic	 dyskinesia	 [PNKD],	
oculogyric	 crises,	 and	 fatigue)	 that	 suggest	 a	 high	 probability	 of	
GLUT1DS	 as	 a	 clinical	 diagnosis	 (De	 Giorgis,	 Varesio,	 Baldassari,	
Olivotto,	&	Veggiotti,	2016).
Epilepsy	 occurs	 in	 about	 90%	of	 cases	 and	 seizure	 types	 vary	
widely	 as	 follows	 in	 order	 of	 frequency:	 generalized	 tonic‐clonic	
seizures	(GTCs),	absence,	complex	partial,	myoclonic,	drop	attacks,	
tonic,	 simple	 partial,	 infantile	 spasms,	 and	 epileptic	 spasms	 (Pong	
et	al.,	2012).	KD	was	proven	to	have	an	anticonvulsant	property	in	
many	 studies	 (Kass,	Winesett,	 Bessone,	 Turner,	 &	 Kossoff,	 2016;	
Leen	et	al.,	2010;	Pong	et	al.,	2012;	Ramm‐Pettersen	et	al.,	2013)	but	
the	underlying	mechanism	 is	not	 completely	understood	 (Clanton,	
Wu,	 Akabani,	 &	 Aramayo,	 2017;	 Politi,	 Shemer‐Meiri,	 Shuper,	 &	
Aharoni,	2011).





Regarding	 cognitive	 impairment	 in	 GLUT1DS	 patients,	 several	
reports	describe	a	mild	or	moderate‐severe	mental	disability	(with‐
out	a	clear	definition	of	degree),	 in	most	cases	proportional	to	dis‐
ease's	 severity	 (Hully	 et	al.,	 2015;	 Larsen	 et	al.,	 2015;	 Leen	 et	al.,	
2010;	Tzadok	et	al.,	2014)	(for	an	overview	of	literature	see	Table	1).	
Hully	 et	al.	 (2015)	 observed	 that	 patients	with	myoclonic	 seizures	
have	 a	 higher	 likelihood	 of	 cognitive	 impairment.	 Ito	 et	al.	 (2015)	
found that mental disability was more severe in patients with earlier 
disease	onset;	furthermore,	they	found	a	better	cognitive	outcome	
in	patients	with	missense	mutations,	higher	CSF/blood	glucose	ratio,	

















2014),	 both	 expressive	 and	 receptive	 language	 (3/6	 patients	 in	
Ramm‐Pettersen	et	al.,	2014),	and	sensorimotor	speed	(1/6	patients	
in	 Ramm‐Pettersen	 et	al.	 2014).	 Total	 IQ	 improvement	was	 found	






et	al.	 2014	 after	 14	months	 of	 KD,	 a	 patient	 gained	 21	 points	 of	
TIQ	 from	 42	 to	 63	 on	Wechsler	 Preschool	 and	 Primary	 Scale	 of	
Intelligence	 (WPPSI	 III)	 (Wechsler,	 2008);	 a	 patient	 in	 De	 Giorgis	
et	al.	2015,	after	2	years	of	diet,	gained	10	points	of	TIQ	from	79	to	
89	on	WISC	III.	Besides	these	rare	reports,	the	cognitive	profile	 in	
GLUT1DS	has	not	been	deeply	 characterized	 so	 far.	Effectiveness	
of the diet on cognition is probably difficult to assess because of the 
presence of other genetic and environmental factors that could be 
involved in the outcome.
The aim of our study was to describe the cognitive profile in 
GLUT1DS	patients,	before	and	after	 the	KD	 introduction,	 in	order	











children's parents and patients. The study was approved by the 
Ethics	Committee	of	our	Institute.
For	each	patient	included	in	the	study,	information	such	as	type	
of	GLUT1	mutation,	 cerebrospinal	 fluid	 (CSF)/blood	 glucose	 ratio,	
type	 of	 seizure,	 type	 of	 movement	 disorder,	 intelligence	 quotient	
(IQ)	[total	(TIQ),	verbal	(VIQ),	and	performance	(PIQ)],	and	response	
to	the	KD	were	collected.	Classical	KD	was	given	in	4:1,	3:1,	or	2:1	
ratio	 (grams	 of	 fat:	 carbohydrates	 plus	 proteins)	 in	 order	 to	 ob‐
tain	beta‐hydroxybutyrate	 levels	between	2	and	6	mmol/L	 in	each	
patient.

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Standard	 cognitive	 tests	 measured	 with	 Wechsler	 Intelligence	
Scales	 (Wechsler,	1995,	2012)	 according	 to	 the	age	of	 the	patient	
were	conducted	at	T0,	T1,	and	T2.	Test	administration	was	carried	
out individually by a professional neuropsychologist. Testing was 





function and its domain.
2.4 | Statistical analyses
Statistical	 analysis	 was	 performed	 using	 SPSS	 statistical	 software	
version	19.0	for	Windows	(SPSS	Inc.,	Chicago,	IL).	After	testing	for	
normal	 distribution	by	mean	of	 the	Kolmogorov–Smirnov	 test,	we	




absolute numbers and percentages.
Correlation analysis was then used to identify potential influenc‐
ing	factors	for	IQ	amelioration	in	the	whole	sample.	Nonparametric	
correlation	coefficient	 (Spearman's	Rho)	was	used,	considering	the	






We confirm that we have read the Journal's position on issues in‐
volved in ethical publication and affirm that this report is consistent 
with those guidelines.
3  | RESULTS
Our	 sample	 (presented	 in	 detail	 in	 Table	2)	 includes	 25	 patients	
(seven	 males	 and	 18	 females)	 aged	 between	 3.7	 and	 40	years	
(mean	13.16	years),	with	established	diagnosis	of	GLUT1	deficiency	














sults	 in	Supplementary	Table	A).	The	median	scores	were:	 total	 IQ	
of	61	(range:	40–99,	IQR	(interquartile	range):	29),	VIQ	of	66	(range:	
45–118;	IQR:	38),	and	PIQ	of	68	(range:	45–98;	IQR:	32).














tients	 with	 mild	 cognitive	 impairment	 presented	 at	 the	 opposite,	
having	lower	VIQ	scores	than	PIQ	in	50%	of	the	patients.
Dividing	the	subjects	into	four	groups	according	to	the	TIQ,	we	




Taking	 into	 consideration	 PIQ,	 the	 specific	 subtests(detailed	
description	of	 results	 in	 Supplementary	Table	B)	 that	were	mostly	
affected were Picture Completion with a median standard score of 
5	(range:	1–8;	IQR:	5);	Coding‐Digit	Symbol	with	a	median	standard	
score	4.5	 (range:	1–9;	 IQR:	3);	Picture	Arrangement	with	a	median	
standard	 score	 of	 3	 (range:	 1–9;	 IQR:	 1);	 and	Block	 design	with	 a	
median	standard	score	of	5	(range:	1–9;	IQR:	4.75).
3.1 | KD follow‐up evaluations (T1, 18 months)
Cognitive	 data	 after	 18	months	 of	 follow‐up	 (T1)	 were	 available	
in	 14	 patients.	 Among	 these,	 median	 IQ	 scores	 varied	 with	 an	
improvement	 in	 TIQ	 from	55.5	 (range:	 43–99;	 IQR:	 25.75)	 to	 58	








Correlation	 between	 IQ	 evolution	 (total,	 verbal,	 and	 perfor‐
mance)	 and	 type	of	mutation	was	 attempted,	 but	we	did	 not	 find	
any	 statistically	 significant	 result,	 likewise	 for	 type	 of	 seizure	 and	
movement disorder.
Instead,	 correlation	 between	 CSF/blood	 glucose	 ratio	 and	 IQ	
(total,	verbal	and	performance)	showed	an	improvement	of	TIQ	and	
VIQ	from	T0	to	T1	among	patients	with	higher	CSF/blood	glucose	




F I G U R E  1   IQ	(Intelligence	Quotient)	scores	at	different	time	points	during	the	follow‐up.	In	green	Normal	IQ,	in	yellow	Borderline	IQ,	
in	orange	Mild	Cognitive	impairment	(ID)	and	in	red	moderate	Cognitive	impairment.	The	arrows	point	out	the	patients	that	had	an	IQ	
amelioration	passing	from	moderate	IQ	to	Mild	IQ,	or	from	Mild	IQ	to	Borderline	IQ,	or	from	Borderline	IQ	to	Normal	IQ
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group	(0.36–0.39),	and	“severely	low	ratio”	group	(≤	0.35).	IQ	(total,	
verbal	and	performance)	evolution	in	relation	to	CSF/blood	glucose	













verbal	 IQ	with	a	worsening	 in	TIQ	and	PIQ;	older	age	group	 (mean	
19.5	years)	acquired	the	lowest	IQ	scores	(TIQ,	VIQ	and	PIQ)	at	T1.









So	 far,	 most	 literature	 data	 focused	 on	 GLUT1DS	 general	 clinical	
profile in both pediatric and adult populations with predominantly 
qualitative description of cognitive function. The majority of reports 
try	to	correlate	KD	response	with	general	outcome	of	al	lGLUT1DS	
symptoms and describe cognitive and behavioral aspects when 
available.
F I G U R E  3  CSF/blood	glucose	ratio	and	its	corresponding	WISC‐III	Scores	at	T0	(baseline)	and	at	T1	(18th	month	of	KD).	Severely	Low	
Ratio	(0.33–0.35)	(three	patients);	Moderately	Low	Ratio	(0.38–0.39)	(four	patients);	Low	Ratio	(0.44–0.56)	(six	patients)
F I G U R E  4  CSF/blood	glucose	ratio	and	its	corresponding	WISC‐III	Scores	at	T0	(baseline),	T1	(18th	month	of	KD)	and	T2	(36th	month	of	
KD).	Severely	Low	Ratio	(0.33–0.35)	(one	patient);	Moderately	Low	Ratio	(0.38–0.39)	(two	patients);	Low	Ratio	(0.44–0.56)	(three	patients)






Analyzing	 each	 Wechsler	 Intelligence	 Scales	 (Wechsler,	
1995,	 2012)	 subtest,	 we	 identified	 a	 major	 impairment	 in	 perfor‐
mances	 such	as	Completion	 subtest,	Coding‐Digit	 Symbol,	Picture	
Arrangement,	and	Block	design.	Low	scores	 in	Picture	Completion	
subtest	 reveals	 an	 impairment	 in	 attention	 capacity,	 ability	 to	 ob‐
serve	 details,	 and	 recognize	 specific	 features	 of	 the	 environment.	
Low	 scores	 in	 Coding‐Digit	 Symbol	 imply	 an	 impairment	 in	 visual	
motor	 speed,	 motor	 coordination,	 memory,	 and	 visual	 analysis.	
Deficient	 scores	 in	 Picture	 Arrangement	 pertain	 to	 impairments	
in	 nonverbal	 reasoning,	 sequencing	 skills,	 temporospatial	 analysis,	
mental	 anticipation,	 planning	 capacity,	 speed,	 accuracy,	 and	 grasp	
of	social	cause	and	effect	(also	known	as	social	intelligence).	Lastly,	
deficient	 scores	 in	 Block	Design	 reveal	 impairments	 in	 visual	 per‐
ceptual	skills,	speed,	spatial	problem‐solving,	manipulative	abilities,	
coordination,	and	fluid	intelligence.
Considering	 typical	 clinical	 profile	 of	 GLUT1DS	 patients	 with	
prominent	extrapyramidal	symptoms	such	as	motor	incoordination,	
dysarthria,	fatigue,	continuous	and	paroxystic	movement	disorders,	





we	 can	 speculate	 that	GLUT1DS	patients	 have	 a	 typical	 cognitive	
profile with greater difficulties in visuospatial and visuomotor skills. 
Therefore,	according	to	this	evidence,	we	suggest	a	complete	neu‐





there is no direct correlation between type of mutation and cogni‐
tive	impairment,	as	was	noted	by	Ito	et	al.	(2015);	nor	with	type	of	
movement	 disorder	 or	 type	 of	 seizure	 as	 observed	 by	Hully	 et	al.	
(2015).
On	the	other	hand,	we	found	a	significant	direct	correlation	be‐
tween	 IQ	 (particularly	 TIQ	 and	VIQ)	 and	CSF/blood	 glucose	 ratio	
values	in	short‐term	follow‐up	(T1).	Higher	CSF/blood	glucose	ratio	
corresponded	to	a	better	cognitive	improvement	in	response	to	KD	









transporter	 defect,	 especially	 in	 patients	 with	 severely	 low‐ratio	
values.
In	 a	 longitudinal	 study,	 Alter	 et	al.	 (2015)	 found	 that	 patients	




mature brain. They placed the vulnerability period between first and 
sixth	months	after	birth,	so	they	stated	that	diagnosis	and	treatment	





medium term of the diet.
Those patients who started diet before 6 years of age achieved 
a better cognitive outcome; those who started between 6 and 
12	years	had	a	moderate	decline	of	total	IQ	(with	a	stable	VIQ	and	
worse	PIQ).	GLUT1DS	patients	who	started	KD	in	adolescence	suf‐
fered the worst cognitive evolution.
Our	 results	 are	 consistent	 with	 the	 hypothesis	 that	 timing	 of	
KD	introduction	is	a	predictive	factor	for	cognitive	outcome	in	pa‐
tients	 with	 GLUT1DS	 and	 that	 an	 earlier	 introduction	 of	 the	 diet	
may	prevent	not	only	epilepsy	and	movement	disorder	onset	 (pre‐
viously	widely	demonstrated	by	different	studies	(Kass	et	al.,	2016;	





Although	duration	of	dietary	 therapy	was	not	clearly	 stated	 in	
GLUT1DS	 therapeutic	 guidelines,	 physicians	 agree	 about	 obvious	
efficacy	 and	 good	 tolerability	 of	 KD	 on	 epilepsy	 and	 involuntary	
movements	in	the	long	term.	So	far,	less	data	are	available	in	litera‐
ture	about	cognition,	but	studies	available	showed	a	better	cognitive	
outcome in patients with earlier diagnosis and early introduction of 
KD	(Ramm‐Pettersen	et	al.,	2013).	Our	data	confirm	that	an	early	KD	
introduction and a good compliance to the diet are predictive also of 
a	better	cognitive	outcome,	and	our	study	confirms	that	prolonged	
treatment	 with	 KD	 is	 needed	 in	 order	 to	 increase	 the	 chance	 of	








able ratios—but more frequently 3:1 or 2:1—with the aim of main‐
taining	beta‐hydroxybutyrate	levels	between	2	and	6	mmol/L	which	
have guaranteed the compliance to all of the patients recruited in 
our	study	and	allowed	a	good	efficacy	response	in	terms	of	epilepsy,	
movement	disorder,	and	cognition.
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other environmental or unknown genetic factors could influence 




Based	 on	 our	 cognitive	 results,	 we	 suggest	 applying	 to	 all	
GLUT1DS	 patients	 a	 complete	 neuropsychological	 investigation,	
studying in detail the visuospatial and visuomotor skills which were 
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